...Patients with high expression of PD-L1 (TPS>=50%) who were provided with detectable tissue samples before enrollment and confirmed by Dako 22C3; 6. ...

Sintilimab (200 mg) and docetaxel (75 mg/m2) were administered every 3 weeks until progression....Patients detected with high PD-L1 expression in circulating tumor cells (cutoff value ≥32.5% based on the median CTC-PD-L1 expression) achieved significantly higher ORR (60% versus 13.3%, p = 0.021) and significantly longer median PFS (6.0 versus 3.5 months, p = 0.011) and median OS (15.8 versus 9.0 months, p = 0.038) than those with low CTC-PD-L1 level.

Pre-immunotherapy treatment tumor samples from twenty-nine NSCLC patients who received neoadjuvant immunotherapy with sintilimab, an anti-PD-1 drug, were subjected to targeted DNA sequencing and PD-L1 immunochemistry staining....Herein, we reevaluated PD-L1 expression with the 22C3 anti-PD-L1 antibody (Dako)...TPS was positively correlated with the degree of pathologic regression (Fig. 1a, R = 0.40, p = 0.04)….Expression of PD-L1 scores of TPS ≥ 50%, TPS 1–49% and TPS < 1% were observed in 10, 9, 9 samples, respectively. The rates of MPR in the three groups were 70% (7/10), 22% (2/9), 22% (2/9), respectively (Fig. 1c). Thus, a TPS of 50% or higher was significantly associated with MPR by Fisher’s exact test (p = 0.02, Fig. 1c, d).